针对心血管疾病的创新治疗策略
1Cellular and Molecular Signaling, New York, New York 10022.
EXCLI journal
|August 18, 2023
概括
心血管疾病是导致死亡的主要原因,需要超越传统风险因素的新策略. 针对涉及SIRT1,FoxOs和AMPK的途径,为心脏病提供了新的治疗潜力.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 非传染性疾病 非传染性疾病
背景情况:
- 心血管疾病 (CVD) 是全球主要的健康挑战,也是导致死亡的主要原因.
- 传统的风险因素,如高胆固醇,高血压和糖尿病,并不能完全预防心血管疾病的发病或进展.
- 针对潜在的心血管疾病机制的新型治疗策略至关重要.
研究的目的:
- 探索SIRT1,FoxOs和AMPK通路在心血管健康和疾病中的作用.
- 了解这些分子通路之间的复杂关系.
- 确定治疗心血管疾病的临床翻译的潜在目标.
主要方法:
- 关于SIRT1,FoxOs和AMPK在心血管环境中的科学文献的审查.
- 分析分子机制,包括基因素脱乙烯化,代谢调节和细胞应激反应.
- 检查这些途径在氧化应激,炎症和衰老等条件下的相互作用.
主要成果:
- SIRT1限制心血管损伤,有助于干细胞的发育,并通过NAD+途径调节新陈代谢.
- 狐通过减少氧化应激和通过自和亡促进修复来调节心脏病.
- AMPK对于心脏代谢,胰岛素敏感性,线粒体功能和炎症控制至关重要.
结论:
- SIRT1,FoxOs和AMPK通路的复杂相互作用为新的心血管治疗提供了有希望的途径.
- 为了成功的临床转化,需要对这些分子网络进行进一步的详细洞察.
- 针对这些途径可以为打击心血管疾病提供新的希望.
相关概念视频
01:27Coronary Artery Disease V: Interprofessional Care
9
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
9
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11